Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.

Archives of toxicology - 1 Apr 2014

Lin Victor C, Huang Chao-Yuan, Lee Yung-Chin, Yu Chia-Cheng, Chang Ta-Yuan, Lu Te-Ling, Huang Shu-Pin, Bao Bo-Ying

Abstract excerpt

Since the tumor protein p53 (TP53), a transcription factor, plays a crucial role in prostate cancer development and progression, we hypothesized that sequence variants in TP53 binding sites might affect clinical outcomes in patients with prostate cancer. We systematically evaluated 41 single nucleotide polymorphisms (SNPs) within genome-wide predicted TP53 binding sites in a cohort of 1,024 prostate cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Logistic Models

Share to Proportional Hazards Models

Share to Prostatectomy

Share to Prostatic Neoplasms

Share to Protective Factors

Source

Identifiers

PMID: 24448834
DOI: 10.1007/s00204-014-1196-8

Genes

EXOC4
DAB2
FRK
TRPS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.PMID 24448834Read ↗

Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients.Semantic proximity Read ↗

PTBP1 Genetic Variants Affect the Clinical Response to Androgen-deprivation Therapy in Patients With Prostate Cancer.Semantic proximity Read ↗

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of MenSemantic proximity Read ↗

Evaluation of the Prognostic Role of TP53 Gene Mutations in Prostate Cancer Outcome: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy.Semantic proximity Read ↗

Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.Semantic proximity Read ↗

Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.Semantic proximity Read ↗

Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy.Semantic proximity Read ↗

Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.Semantic proximity Read ↗

Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures and serum samples from a European Caucasian populationSemantic proximity Read ↗

Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosis.Semantic proximity Read ↗

Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.